Forte Biosciences (FBRX) Asset Utilization Ratio (2018 - 2019)
Forte Biosciences' (FBRX) quarterly Asset Utilization Ratio came in at 0.0 in Q4 2019, down 99.51% year-on-year from 0.19 in Q4 2018, and up 98.94% on a QoQ basis from 0.0 in Q3 2019.
Forte Biosciences (FBRX) Asset Utilization Ratio (2018 - 2019) Analysis & Trends
Forte Biosciences (FBRX) has 2 years of Asset Utilization Ratio data on file, last reported at 0.0 in Q4 2019.
- On a quarterly basis, Asset Utilization Ratio fell 99.51% year-over-year to 0.0 in Q4 2019; TTM through Dec 2019 was 0.0, a 99.51% decrease from a year earlier, with the FY2019 full-year figure at 0.0, down 99.65% from the prior year.
- Asset Utilization Ratio for Q4 2019 stood at 0.0, up from 0.0 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for FBRX reached as high as 0.2 in Q3 2018 and fell as low as 0.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.69 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 0.00 |
| Sep 30, 2019 | 0.00 |
| Jun 30, 2019 | 0.20 |
| Mar 31, 2019 | 0.18 |
| Dec 31, 2018 | 0.19 |
| Sep 30, 2018 | 0.20 |
| Jun 30, 2018 | 0.00 |
| Mar 31, 2018 | 0.00 |